drugset / Trial / NCT04355169

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

NCT04355169

Phase 2 Terminated 2 enrolled Shionogi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to compare the efficacy of naldemedine versus placebo and to assess its effect on the time to gastrointestinal (GI) recovery following surgeries that include bowel resection and bowel transection.

Timeline

Start
2020-11-06
Primary completion
2021-01-04
Completion
2021-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Naldemedine Other / unclassified 1.25 mg Oral
Subject Naldemedine Other / unclassified 2.5 mg Oral
Subject Naldemedine Other / unclassified 5 mg Oral